Reduction of asthma exacerbation rate in children by non-invasive monitoring of inflammatory markers in exhaled breath (condensate): the RASTER study
- Conditions
- allergic asthmaasthmabronchial asthma10006436
- Registration Number
- NL-OMON36640
- Lead Sponsor
- Medisch Universitair Ziekenhuis Maastricht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
The specific inclusion criteria are: 1) already known with a diagnosis of asthma during at least 6 months; 2) age between 6 and 16 years; 3) reversibility to a bronchodilator (increase in FEV1 > 9% of predicted value; and/or 4) bronchial hyperresponsiveness to PC20 histamine < 8 mg/ml; and/or 5)only the use of fluticason in case of inhaled corticosteroid therapy and 6) the use of inhaled corticosteroids.
Exclusion criteria are: 1) cardiac abnormalities; 2) mental retardation, congenital abnormalities or existence of a syndrome; 3) active smoking; 4) no technical satisfactory performance of measurements; 5) no phone line or internet assess available at home; 6) allergen immunotherapy during the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.